High-Purity 3-Fluoro-4-Methoxy-Benzenamine Specifications for Pharmaceutical Intermediates
- CAS 366-99-4 Compliance: Ensures molecular identity (C7H8FNO) and regulatory alignment for drug substance filings.
- Advanced Analytics: Verification of ≥99.0% purity via GC and HPLC methods to detect fluorinated impurities.
- Bulk Procurement: Scalable manufacturing processes offering significant cost advantages over legacy small-scale pricing.
In the landscape of modern medicinal chemistry, the availability of reliable fluorinated building blocks is critical for optimizing metabolic stability and bioavailability in drug candidates. 3-Fluoro-4-methoxy-benzenamine serves as a pivotal intermediate in the synthesis of kinase inhibitors and agrochemical agents. For process chemists and procurement specialists, understanding the technical specifications beyond the basic CAS number is essential for ensuring batch-to-batch consistency and regulatory compliance. As a premier global manufacturer, NINGBO INNO PHARMCHEM CO.,LTD. adheres to stringent quality control protocols to deliver materials suitable for GMP environments.
Critical Quality Attributes for Pharmaceutical-Grade Intermediates
The quality of aniline derivatives is often defined by the presence of isomeric impurities and residual starting materials. When evaluating industrial purity standards, buyers must look beyond a simple percentage claim. The molecular formula C7H8FNO corresponds to a molecular weight of 141.15 g/mol, but slight variations in the substitution pattern can lead to downstream reaction failures. Common synonyms encountered in supply chains include 4-Amino-2-fluoroanisole and 3-fluoro-p-anisidine. However, precise nomenclature is vital for inventory management and safety data sheet (SDS) alignment.
Physical properties serve as the first line of verification upon receipt of goods. The boiling point is typically recorded at 135°C under 18.0 mmHg pressure. Deviations from this range may indicate the presence of higher boiling oligomers or solvent residues. The following table outlines the critical physical and chemical specifications required for high-grade procurement:
| Parameter | Specification Standard | Analytical Method |
|---|---|---|
| Appearance | Off-white to light yellow crystalline powder or liquid | Visual Inspection |
| Purity (GC) | ≥ 99.0% Area Normalization | Gas Chromatography |
| Water Content | ≤ 0.5% | Karl Fischer Titration |
| Boiling Point | 135°C ± 2°C (at 18 mmHg) | Distillation |
| Heavy Metals | ≤ 10 ppm | ICP-MS |
Maintaining these specifications requires a robust synthesis route that minimizes side reactions. Traditional reduction methods of the corresponding nitro compounds must be carefully controlled to prevent over-reduction or dehalogenation, which can introduce defluorinated impurities that are difficult to separate.
Analytical Methods for Verifying ≥99.0% Purity
Reliable quantification of purity is non-negotiable for pharmaceutical intermediates. While certificate data is provided by the supplier, internal validation is often required for regulatory submissions. Gas Chromatography (GC) is the preferred method for volatile anilines like this compound, offering high resolution for separating the target molecule from isomeric byproducts. A typical method utilizes a capillary column with a flame ionization detector (FID), ensuring that the area percentage reflects the true chemical composition.
For structural confirmation, Proton Nuclear Magnetic Resonance (1H NMR) and Carbon NMR (13C NMR) are indispensable. The fluorine atom introduces distinct coupling patterns in the aromatic region, which serves as a fingerprint for the 3-fluoro-4-methoxy substitution pattern. Specifically, the coupling constant between the fluorine and adjacent protons confirms the regiochemistry, distinguishing it from other isomers such as 3-fluor-4-methoxyanilin variants that might arise from alternative manufacturing pathways. High-Performance Liquid Chromatography (HPLC) is also employed, particularly when assessing non-volatile impurities or when the compound is part of a stability-indicating method.
Interpreting Certificate of Analysis (COA) for Regulatory Submissions
The Certificate of Analysis (COA) is the primary document governing the acceptance of chemical materials into a quality control laboratory. A comprehensive COA must include not only the batch number and manufacturing date but also detailed test results against established specifications. For CAS 366-99-4, the COA should explicitly state the method used for purity determination (e.g., GC vs. HPLC) and the reference standards employed. Regulatory bodies require traceability, meaning the impurity profile must be documented, especially for known genotoxic impurities or heavy metals.
When sourcing high-purity 3-Fluoro-4-methoxyaniline, buyers should verify that the COA includes stability data and storage recommendations. Given the sensitivity of anilines to oxidation, proper packaging under inert atmosphere is often noted in the handling instructions. Furthermore, the safety profile indicates the material is harmful if swallowed, in contact with skin, or if inhaled, necessitating strict adherence to GHS P statements regarding protective equipment and emergency measures.
Market Trends and Bulk Procurement Strategy
Historical pricing data for fluorinated anilines has shown significant volatility, often driven by raw material availability and environmental compliance costs in manufacturing regions. Over the past several years, market analysis indicates a trend where small-scale research quantities commanded premium pricing, often exceeding hundreds of dollars per hundred grams. However, established supply chains have optimized production, leading to more competitive bulk price structures for industrial-scale orders. Procurement teams should focus on long-term contracts with verified manufacturers to lock in rates and ensure supply continuity.
NINGBO INNO PHARMCHEM CO.,LTD. leverages advanced process chemistry to maintain consistent quality while optimizing cost efficiency for large-volume clients. By controlling the entire manufacturing process from raw material sourcing to final purification, the company ensures that every batch meets the rigorous demands of the pharmaceutical industry. Whether for early-stage drug discovery or commercial API production, securing a reliable supply of this key intermediate is fundamental to project success.
In conclusion, the technical evaluation of 3-Fluoro-4-methoxy-benzenamine requires a multifaceted approach involving strict physical testing, advanced spectroscopic verification, and thorough documentation review. By prioritizing suppliers who provide transparent COAs and demonstrate mastery over the synthesis route, pharmaceutical companies can mitigate risk and accelerate their development timelines.